- Report
- January 2026
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- March 2023
- 185 Pages
Global
From €3897EUR$4,450USD£3,383GBP
Nitrogen-13 (N-13) is a radioactive isotope of nitrogen used in Nuclear Medicine and Radiopharmacology. It is produced in a cyclotron by bombarding nitrogen gas with protons. N-13 is used in positron emission tomography (PET) imaging to diagnose and monitor diseases such as cancer, heart disease, and neurological disorders. It is also used in research to study the metabolism of drugs and other compounds.
N-13 is available in a variety of forms, including solutions, kits, and kits with radiopharmaceuticals. It is typically supplied in vials or syringes, and is administered intravenously or orally. The half-life of N-13 is approximately 10 minutes, making it ideal for short-term imaging studies.
Companies in the N-13 market include GE Healthcare, Bracco Diagnostics, Mallinckrodt Pharmaceuticals, and Jubilant DraxImage. Show Less Read more